At a glance, Peter Calveley is purpose built for his role as Chief Operating Officer of Westlake Village BioPartners. Prior to joining Westlake, Calveley was a Managing Director in the Investment Banking Group at SVB Leerink based out of San Francisco and was responsible for companies in the biotech sector in the Western U.S. and Canada.
During his 12-year tenure in investment banking, Calveley developed strategy for and executed financing transactions for clients including initial public offerings, follow-on offerings, royalty sales and convertible note offerings, raising over $5 billion in capital. Calveley also advised on and executed a variety of strategic transactions including buy-side M&A, sell-side M&A and reverse mergers.
Calveley’s role at Westlake includes fund management, finances, LP relationships, and enabling Westlake to enhance strategic decision-making regarding financing, business development and M&A for the portfolio companies. One of Calveley’s key responsibilities will be further developing and leveraging co-investor, investment banking and strategic partner relationships for Westlake and their portfolio companies.
Calveley began his investment banking career with Merrill Lynch in the Global Healthcare Investment Banking Group in San Francisco after completing his MBA at UCLA Anderson School of Management. Prior to transitioning to the business side of biotech, Calveley was a member of the drug discovery team at Alexion Pharmaceuticals and holds a Bachelor of Science (Honours) degree in biochemistry from Queen’s University.
It was while working in drug discovery with Alexion Pharmaceuticals that he started doing evening programs at the graduate school at University of California San Diego where he “fell in love with the business side of biopharma,” he says.
This newest phase in his career with Westlake Village BioPartners marks a return to his biotech roots. “I want to get closer to the science, closer to the entrepreneurs and interact with the industry in a different way,” he says. “I am excited to help nurture companies from a very early stage where I can have a meaningful impact.”
